Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
CC transcript
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A JANUS HENDERSON GROUP PLC reports a 15.4% stake in MADRIGAL PHARMACEUTICALS, INC.
10/05/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 10% stake in Madrigal Pharmaceuticals, Inc.
10/05/2023 4 BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.
Txns: Bought 125,447 warrants @ $0.0001, valued at $12.5
Bought 1,522,651 warrants @ $0.0001, valued at $152.3
10/02/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] Warrant No. Original Issue Date: [ ], 2023 MADRIGAL PHARMACEUTICALS, INC.",
"Hogan Lovells US LLP"
10/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 8.4% stake in Madrigal Pharmaceuticals, Inc.
08/08/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/08/2023 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/17/2023 8-K Quarterly results
07/12/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis"
05/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/09/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Sales Agreement, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC",
"Legal Opinion of Hogan Lovells US LLP"
05/09/2023 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/02/2023 4 Waltermire Robert E. (Senior VP, Chief Pharma Dev.) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.
Txns: Sold 900 shares @ $271.03, valued at $243.9k
Sold 4,100 shares @ $272.3, valued at $1.1M
Sold 1,928 shares @ $273.44, valued at $527.2k
Sold 1,672 shares @ $274.57, valued at $459.1k
Sold 1,300 shares @ $275.53, valued at $358.2k
Sold 100 shares @ $276.19, valued at $27.6k
Exercised 5,000 options to buy @ $87.92, valued at $439.6k
Exercised 5,000 options to buy @ $87.92, valued at $439.6k
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results"
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 9% stake in MADRIGAL PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 1.2% stake in MADRIGAL PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Deep Track Capital, LP reports a 0% stake in Madrigal Pharmaceuticals, Inc.
02/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Tranche 2 Warrant Agreement, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates",
"Loan and Security Agreement, as amended by the First Amendment to Loan and Security Agreement, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or entities from time to time party thereto and Hercules Capital, Inc"
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/19/2023 4 Levy Richard S (Director) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.
Txns: Sold 100 shares @ $285.28, valued at $28.5k
Sold 400 shares @ $287.08, valued at $114.8k
Sold 300 shares @ $288.91, valued at $86.7k
Sold 1,600 shares @ $290.36, valued at $464.6k
Sold 3,325 shares @ $291.66, valued at $969.8k
Sold 5,227 shares @ $292.68, valued at $1.5M
Sold 3,548 shares @ $293.54, valued at $1M
Sold 5,164 shares @ $294.68, valued at $1.5M
Sold 2,325 shares @ $295.45, valued at $686.9k
Sold 500 shares @ $296.68, valued at $148.3k
Exercised 12,489 options to buy @ $105.08, valued at $1.3M
01/18/2023 4 Sukhija Remy (Chief Commercial Officer) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.
Txns: Granted 15,001 shares @ $0
01/18/2023 4 Waltermire Robert E. (Senior VP, Chief Pharma Dev.) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.
Txns: Granted 5,667 shares @ $0
01/18/2023 4 Lynch Brian Joseph (SVP and General Counsel) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.
Txns: Granted 15,001 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy